Characterization of VRC01, a potent and broadly neutralizing anti‐HIV mAb, produced in transiently and stably transformed tobacco

The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV‐1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most important target population, the poor in under‐develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Teh, Audrey Y‐H., Maresch, Daniel, Klein, Katja, Ma, Julian K‐C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Pub 2013
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112721/
https://www.ncbi.nlm.nih.gov/pubmed/24256218
http://dx.doi.org/10.1111/pbi.12137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112721/
https://www.ncbi.nlm.nih.gov/pubmed/24256218
http://dx.doi.org/10.1111/pbi.12137

Ejemplares similares